IP Library Granted Patent US 7,217,738
Granted Patent B2
US 7,217,738 · App. 11/049,447 · Granted May 15, 2007

β2-adrenergic receptor agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,217,738
App. No.
11/049,447
Granted
May 15, 2007
Kind
B2
Abstract

Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

Claims (13)

1. A method of treating a mammal having a disease or condition associated with β 2 adrenergic receptor activity, the method comprising administering to the mammal, a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of the formula:

or a pharmaceutically-acceptable salt thereof.

2. A method of treating a mammal having a disease or condition associated with β 2 adrenergic receptor activity, the method comprising administering to the mammal, a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of the formula:

wherein the stereochemistry at *C and **C is (RS) and (RS), (R) and (R), (R) and (S), (S) and (R), or (S) and (S); or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the stereochemistry at *C is (R) and the stereochemistry at **C is (R).

4. The method of any one of claims 1 to 3 wherein the disease or condition is selected from asthma, chronic bronchitis, chronic obstructive pulmonary disease, nervous system injury, and premature labor.

5. The method of any one of claims 1 to 3 wherein the disease or condition is a respiratory disease.

6. The method of claim 5 wherein the respiratory disease is asthma or chronic obstructive pulmonary disease.

7. The method of any one of claims 1 to 3 further comprising administering a therapeutically effective amount of a steroidal anti-inflammatory agent.

8. A method of treating asthma in a mammal, the method comprising administering to the mammal, a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically effective amount of a compound of the formula:

wherein the stereochemistry at *C and **C is (R) and (R), or a pharmaceutically acceptable salt thereof.

9. A method of treating asthma in a mammal, the method comprising administering to the mammal, a pharmaceutical composition comprising a pharmaceutically-acceptable carrier; a therapeutically effective amount of a compound of the formula:

wherein the stereochemistry at *C and **C is (R) and (R), or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a steroidal anti-inflammatory agent.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2014
From: THERAVANCE, INC.
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 033181/0693 →